Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.25p +5.21% 25.25p 25.00p 25.50p 25.25p 24.00p 24.00p 495,792.00 16:16:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.5 -12.1 -2.3 - 149.84

Allergy Therapeutics Share Discussion Threads

Showing 3301 to 3325 of 3325 messages
Chat Pages: 133  132  131  130  129  128  127  126  125  124  123  122  Older
DateSubjectAuthorDiscuss
20/1/2017
08:04
Wonder why they didn't just say it plainly in the trading update instead of paying Hardman to do it.
paleje
20/1/2017
07:59
I am sure that you are not on your own AU. Watch this space.
jimmyloser
20/1/2017
07:38
All lining up for the share price to make an assault on 30p.....But when this will happen who knows! I'd be happy with a pull back in the short term so I can top up.
audigger
20/1/2017
07:25
A new report from Hardman and Co. A clear plan for USA launch!!! http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/20.01.17-investment-driving-market-share-gains.pdf
jimmyloser
19/1/2017
08:00
All good stuff....you never know the share price may rise today!
audigger
19/1/2017
07:22
"We are confident about the full year and look forward to updating shareholders on further progress throughout 2017." Regulatory Further to the Company's announcement on 27 June 2016, the Company has held discussions with the US regulatory authorities in relation to its US Grass MATA MPL programme and is.............. proceeding as planned with the safety trial (G104) in the USA and the Phase II conjunctival provocation test dose selection study (G205) in Europe in 2017, ahead of the planned pivotal Phase III trial (G306).
jimmyloser
18/1/2017
14:56
They seem keen to get hold of shares right now.....I suspect everyone expects a very upbeat trading state but all eyes will be looking for progress in the USA. Mine will
jimmyloser
18/1/2017
14:55
They seem keen to get hold of shares right now.....I suspect everyone expects a very upbeat trading state but all eyes will be looking for progress in the USA. Mine will
jimmyloser
16/1/2017
08:43
Trading update 19th January according to web site
qackers
10/1/2017
19:03
And let's not forget that they have already raised most if not all the cash needed for the US trials
audigger
10/1/2017
14:47
From elsewhere...................... Allergy Therapeutics With a quarter of the UK suffering from hayfever at some point in their lives and 10-30% of the global population afflicted, the European allergy immunotherapy market (AIT) is worth $0.8 billion (£0.66 billion). In the US it is worth more than double that, at $1.7 billion. Look at the potential addressable market and its value surges to around $9 billion. This backdrop is perfect for pharmaceuticals business Allergy Therapeutics (AGY). The allergy vaccination group's profitable European operation is busy gobbling up market share as it gathers financial momentum. Revenue is expected to grow 23% in 2017 thanks to foreign exchange tailwinds, and gross margin should climb 260 basis points to 73.6% as volumes grow on a fixed cost base. Before crucial research and development costs and general operational spend, profit should jump by a third to £19 million, finnCap analysts reckon. Outside the flagship European business, Allergy also houses a US division that is trialing the Pollinex Quattro treatment. While the group continues these studies finnCap thinks it will remain loss-making. Trading at a chunky 45% discount to its peers, with a profitable business and healthy pipeline, the valuation looks unjustified. finnCap believes the shares are worth nearly double at 40p, which would give them a market value of £235 million.
jimmyloser
10/1/2017
08:56
The man from FINN is certainly respected!
jimmyloser
09/1/2017
22:19
I think that you will get your news, just listen to that interview again. Lots of clues impo
jimmyloser
09/1/2017
20:49
Breakout or retrace depending how you look at it! Some positive news on the repeat dose range finder would add further momentum.
audigger
07/1/2017
09:31
Worth listening to - impo http://www.finncap.com/news-insight/allergy-therapeutics-initiation-of-coverage
jimmyloser
06/1/2017
16:18
An encouraging start to the New Year..... Allergy Therapeutics plc 92.8% Potential Upside Indicated by finnCap Allergy Therapeutics plc with EPIC/TICKER LON:AGY had its stock rating noted as ‘Initiates/Starts’ with the recommendation being set at ‘BUY’ this morning by analysts at finnCap. Allergy Therapeutics plc are listed in the Health Care sector within AIM. finnCap have set their target price at 40 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 92.8% from the opening price of 20.75 GBX. Over the last 30 and 90 trading days the company share price has increased 0.67 points and increased 0.57 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 21.27 GBX and the 200 Day Moving Average price is recorded at GBX. The 1 year high share price is 30 GBX while the year low stock price is currently 17.25 GBX. There are currently 598,491,373 shares in issue with the average daily volume traded being 86,871. Market capitalisation for LON:AGY is £122,989,973 GBP.
audigger
15/12/2016
15:43
Should there not be news of the meeting with FDA to agree new dose range finding study soon? They said this would happen in 2016...at least I think they did
audigger
10/11/2016
07:15
Allergy Therapeutics PLC (LON:AGY) Rating The financial company have set price target of GBX 53.00 on Allergy Therapeutics PLC (LON:AGY) shares. This is 130.43% from the last stock close. In a note made public on Wednesday, 2 November, Panmure Gordon maintained their Buy rating on shares of AGY. Allergy Therapeutics plc (LON:AGY) Ratings Coverage Out of 3 analysts covering Allergy Therapeutics PLC (LON:AGY), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 79 is the highest target while GBX 37 is the lowest. The GBX 54 average target is 130.38% above today’s (GBX 23.44) stock price. Allergy Therapeutics PLC has been the topic of 26 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained the stock with “Buy” rating in Friday, June 10 report. On Monday, September 26 the stock rating was maintained by Numis Securities with “Buy”. Panmure Gordon maintained the stock with “Buy” rating in Monday, September 21 report. The rating was maintained by Panmure Gordon on Wednesday, November 2 with “Buy”. The stock of Allergy Therapeutics plc (LON:AGY) has “Buy” rating given on Monday, October 10 by Panmure Gordon. Panmure Gordon maintained Allergy Therapeutics plc (LON:AGY) rating on Wednesday, January 13. Panmure Gordon has “Buy” rating and GBX 51 price target. The firm has “Buy” rating given on Monday, December 7 by Panmure Gordon. Panmure Gordon maintained it with “Buy” rating and GBX 47 target price in Thursday, July 23 report. The rating was maintained by Panmure Gordon on Monday, August 10 with “Buy”. The rating was maintained by Panmure Gordon on Tuesday, September 1 with “Buy”.
jimmyloser
09/11/2016
19:00
Trading update last year was on 17th of November
jimmyloser
03/11/2016
15:59
htTp://www.bencard-as.com/documents/PDF/A4Brochure_spreads_FINAL.pdf
celeritas
02/11/2016
07:06
BENCARD AGAIN!!! 2 November 2016 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") European Patent Office grants new and expanded patent underpinning Allergy Therapeutics' core Microcrystalline Tyrosine technology Patent already granted in the United Kingdom and New Zealand Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, today announces that the European Patent Office has granted a broad technology patent relating to the Company's unique Microcrystalline Tyrosine (MCT) depot adjuvant manufacturing process. This patent covers the novel manufacture and physiochemical characteristics of MCT in combination with one or more antigens, further strengthening the Company's core intellectual property. The granting of this patent further strengthens Bencard Adjuvant Systems, the wholly-owned division of Allergy Therapeutics which specialises in developing and optimising aluminium-free adjuvants for infectious diseases. Recent data generated have shown how MCT has a synergistic effect when coupled with another adjuvant from BAS's portfolio, Virus Like Particles (VLP), to create the adjuvant system AdSys-VcT. As recently announced, this adjuvant system demonstrated protective efficacy in a malaria model in a study performed in collaboration with the University of Oxford, UK. Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines, both in allergies and also in infectious disease areas such as malaria and influenza. This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines."
jimmyloser
25/10/2016
21:33
Heading back in to top-up territory
audigger
25/10/2016
09:22
I don't know about The Duke of York, to-day is more of a Humpty Dumpty day! lol
jimmyloser
21/10/2016
11:14
Well sticking with the Duke of York analogy, we walked only part the way up the hill only to be walked back down again!
audigger
17/10/2016
21:51
They have said they will meet with FDA in 2016 so I guess it depends if they RNS the outcome. As for the SP, who knows but it's fun to speculate! I think there's a bit more of a leg up to come this week then we'll stay close to 30.
audigger
Chat Pages: 133  132  131  130  129  128  127  126  125  124  123  122  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170121 23:49:18